MA26623A1 - Composes azapolycycliques condenses a noyau aryle, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Composes azapolycycliques condenses a noyau aryle, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26623A1
MA26623A1 MA25556A MA25556A MA26623A1 MA 26623 A1 MA26623 A1 MA 26623A1 MA 25556 A MA25556 A MA 25556A MA 25556 A MA25556 A MA 25556A MA 26623 A1 MA26623 A1 MA 26623A1
Authority
MA
Morocco
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
azapolycyclic compounds
aryl core
Prior art date
Application number
MA25556A
Other languages
English (en)
Inventor
Wadsworth Jotham
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26623A1 publication Critical patent/MA26623A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MA25556A 1998-04-29 1999-04-28 Composes azapolycycliques condenses a noyau aryle, procede pour leur preparation et compositions pharmaceutiques les contenant MA26623A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8355698P 1998-04-29 1998-04-29

Publications (1)

Publication Number Publication Date
MA26623A1 true MA26623A1 (fr) 2004-12-20

Family

ID=22179102

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25556A MA26623A1 (fr) 1998-04-29 1999-04-28 Composes azapolycycliques condenses a noyau aryle, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (41)

Country Link
US (3) US6462035B1 (fr)
EP (1) EP1076650B1 (fr)
JP (1) JP2002513007A (fr)
KR (1) KR100420423B1 (fr)
CN (1) CN1144787C (fr)
AP (1) AP1154A (fr)
AR (1) AR018596A1 (fr)
AT (1) ATE258921T1 (fr)
AU (1) AU749831B2 (fr)
BG (1) BG64556B1 (fr)
BR (1) BR9910058A (fr)
CA (1) CA2330576A1 (fr)
CO (1) CO5021124A1 (fr)
DE (1) DE69914594T2 (fr)
DK (1) DK1076650T3 (fr)
DZ (1) DZ2778A1 (fr)
EA (1) EA003669B1 (fr)
ES (1) ES2213354T3 (fr)
GT (1) GT199900059A (fr)
HR (1) HRP20000731A2 (fr)
HU (1) HUP0103340A3 (fr)
ID (1) ID26700A (fr)
IL (1) IL138917A0 (fr)
IS (1) IS5649A (fr)
MA (1) MA26623A1 (fr)
MY (1) MY133474A (fr)
NO (1) NO317300B1 (fr)
NZ (1) NZ507035A (fr)
OA (1) OA11506A (fr)
PA (1) PA8471301A1 (fr)
PE (1) PE20000435A1 (fr)
PL (1) PL344010A1 (fr)
PT (1) PT1076650E (fr)
SK (1) SK15952000A3 (fr)
TN (1) TNSN99080A1 (fr)
TR (1) TR200003122T2 (fr)
UA (1) UA61991C2 (fr)
UY (1) UY25636A1 (fr)
WO (1) WO1999055680A1 (fr)
YU (1) YU64400A (fr)
ZA (1) ZA992971B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386024T1 (de) 1997-12-31 2008-03-15 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
CZ20032814A3 (cs) * 2001-04-20 2004-08-18 Pfizeráproductsáinc Způsob přípravy �Ź@@substituovaných indenů a aryl@kondezovaných azapolycyklických sloučenin
BR0213696A (pt) * 2001-10-31 2004-10-26 Pfizer Prod Inc Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas
ATE405574T1 (de) 2001-11-30 2008-09-15 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
US20060089400A1 (en) * 2002-05-03 2006-04-27 The Vernalis Group Of Companies Novel spiro ketone and carboxylic acid derivatives as specific inhibitors for (po3h2) ser/(po3h2)thr-pro-specific peptidyl-prolylcis/trans-isomerases
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
ES2331245T3 (es) * 2003-07-21 2009-12-28 Pfizer Products Inc. Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
ATE395348T1 (de) * 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
US20060210498A1 (en) * 2005-03-18 2006-09-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Novel resorcinol derivatives for skin
US20060210497A1 (en) * 2005-03-18 2006-09-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Novel resorcinol derivatives
DE102005061426A1 (de) * 2005-12-22 2007-07-05 Grünenthal GmbH Substituierte tricyclische Piperidon-Derivate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687937A (en) * 1970-06-23 1972-08-29 Us Of America The 1,5-methano-3-benzazocine derivatives
JPS4914473A (fr) * 1972-06-09 1974-02-07
JPS4924968A (fr) * 1972-07-01 1974-03-05

Also Published As

Publication number Publication date
EA003669B1 (ru) 2003-08-28
NZ507035A (en) 2003-05-30
CO5021124A1 (es) 2001-03-27
PT1076650E (pt) 2004-05-31
KR20010043143A (ko) 2001-05-25
OA11506A (en) 2004-05-14
IL138917A0 (en) 2001-11-25
WO1999055680A1 (fr) 1999-11-04
MY133474A (en) 2007-11-30
ES2213354T3 (es) 2004-08-16
SK15952000A3 (sk) 2002-06-04
ATE258921T1 (de) 2004-02-15
US7122534B2 (en) 2006-10-17
US20030008890A1 (en) 2003-01-09
HK1036453A1 (en) 2002-01-04
CA2330576A1 (fr) 1999-11-04
ID26700A (id) 2001-02-01
DE69914594T2 (de) 2004-12-09
TR200003122T2 (tr) 2001-03-21
PE20000435A1 (es) 2000-05-26
HUP0103340A3 (en) 2002-10-28
DK1076650T3 (da) 2004-05-24
EP1076650A1 (fr) 2001-02-21
CN1144787C (zh) 2004-04-07
NO20005397L (no) 2000-10-26
UY25636A1 (es) 2000-02-23
AP9901524A0 (en) 1999-06-30
US6706702B2 (en) 2004-03-16
HRP20000731A2 (en) 2001-06-30
PA8471301A1 (es) 2000-09-29
NO317300B1 (no) 2004-10-04
AP1154A (en) 2003-03-27
US20040167149A1 (en) 2004-08-26
BG64556B1 (bg) 2005-07-29
UA61991C2 (en) 2003-12-15
BG104983A (en) 2001-09-28
NO20005397D0 (no) 2000-10-26
YU64400A (sh) 2003-01-31
DE69914594D1 (de) 2004-03-11
DZ2778A1 (fr) 2005-04-23
CN1298394A (zh) 2001-06-06
AU2951699A (en) 1999-11-16
EA200000996A1 (ru) 2001-06-25
AR018596A1 (es) 2001-11-28
IS5649A (is) 2000-09-29
GT199900059A (es) 2000-10-11
KR100420423B1 (ko) 2004-03-04
ZA992971B (en) 2000-10-30
TNSN99080A1 (fr) 2005-11-10
BR9910058A (pt) 2000-12-26
JP2002513007A (ja) 2002-05-08
US6462035B1 (en) 2002-10-08
HUP0103340A2 (hu) 2002-02-28
EP1076650B1 (fr) 2004-02-04
AU749831B2 (en) 2002-07-04
PL344010A1 (en) 2001-09-24

Similar Documents

Publication Publication Date Title
MA26589A1 (fr) Composes azapolycycliques a noyau aryle condense, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26680A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26730A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26462A1 (fr) Composes nouveaux a noyau dibenzocycloheptene, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26620A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26748A1 (fr) Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisation
MA26675A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26571A1 (fr) Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
MA26653A1 (fr) Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26505A1 (fr) Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2751334B1 (fr) Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26567A1 (fr) Trifluoromethylethers cycliques a fonction piperidinylaminomethule, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26707A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26619A1 (fr) Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26631A1 (fr) Composes a fonction bis-aminomethyl-carbonyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2757853B1 (fr) Composes de type ceramide, procede pour leur preparation, et composition cosmetique les contenant
MA26603A1 (fr) Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2796940B1 (fr) Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
MA26594A1 (fr) Composes nouveaux inhibiteurs de mmp, procede pour leur preparation et compositions pharmaceutiques les contenant